Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients receiving VCN-01 plus standard gemcitabine/nab-paclitaxel chemo showed markedly better outcomes than chemo alone. Interim data filed with the SEC reveal VCN-01 improved median overall survival to around 11–14 months versus ~8–11 months for chemo-only patients ts2.tech. Notably, patients who received two doses of VCN-01 had median OS of ~14.8 months vs. 11.6 months for chemo alone – a substantial gain in this aggressive cancer ts2.tech. The study met its primary endpoints, with VCN-01 demonstrating a tolerable safety profile and only transient, reversible side effects biospace.com. These positive results – essentially a breakthrough in pancreatic cancer, which notoriously has a very low survival rate – have fueled optimism about Theriva’s approach.
